Darapladib, is a novel inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), an enzyme that may link lipid metabolism with inflammation, leading to the increased stability of atherosclerotic plaques present in the major arteries. Darapladib is being studied as a possible add-on treatment for atherosclerosis.